Results 31 to 40 of about 8,073 (209)
In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors [PDF]
, 2017 Cyclic nucleotide phosphodiesterase enzymes (PDEs) have functions in regulating the levels of intracellular second messengers, 3′, 5′-cyclic adenosine monophosphate (cAMP) and 3′, 5′-cyclic guanosine monophosphate (cGMP), via hydrolysis and decomposing ...
Serdar Durdagi (626227) +2 more
core +1 more source
Frontiers in Oncology, 2019 Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities.
Jo-Fan Chang +10 more
doaj +1 more source
Journal of Medical Internet Research, 2023 BackgroundPatient medication reviews on social networking sites provide valuable insights into the experiences and sentiments of individuals taking specific medications.
Youran Noh, Maryanne Kim, Song Hee Hong
doaj +1 more source
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. [PDF]
Oncotarget, 2017 The combination of pemetrexed and sorafenib has significant clinical activity against a wide variety of tumor types in patients and the present studies were performed to determine whether sildenafil enhances the killing potential of [pemetrexed + sorafenib].
Booth L +3 more
europepmc +4 more sources
Pyrimidinylpyrroloquinolones as Highly Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction [PDF]
, 2016 A series of N-pyrimidinylpyrroloquinolones were discovered as extremely potent and selective PDE5 inhibitors. Representative compounds demonstrated in vivo efficacy in dog erectile dysfunction models and are orally ...
Jihua Guan (2688367) +10 more
core +1 more source
Crude rate for malignant melanoma and control outcomes by exposure to PDE5 inhibitors, and unadjusted and adjusted hazard ratios. [PDF]
, 2016 Crude rate for malignant melanoma and control outcomes by exposure to PDE5 inhibitors, and unadjusted and adjusted hazard ratios.
Ian J. Douglas (370284) +4 more
core +1 more source
PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types [PDF]
, 2015 The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with a clinically relevant NSAID, celecoxib, to kill tumor cells.
Paul Dent +23 more
core +2 more sources
Stimulation of Neural Stem Cell Proliferation by Inhibition of Phosphodiesterase 5
Stem Cells International, 2014 The involvement of nitric oxide (NO) and cyclic GMP (cGMP) in neurogenesis has been progressively unmasked over the last decade. Phosphodiesterase 5 (PDE5) specifically degrades cGMP and is highly abundant in the mammalian brain.
Ana I. Santos +4 more
doaj +1 more source
Phosphodiesterase type 5 inhibitors and erectile dysfunction
South African Family Practice, 2010 Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj +1 more source
Кардиоваскулярная терапия и профилактика, 2018 The review is focused on the issues of erectile dysfunction (ED) management by long term courses of continuous intake of the phosphodiesteraze-5 type (PDE5) inhibitors.
G. G. Sharvadze +3 more
doaj +1 more source